Pluristem Therapeutics Inc.
) announced that it has initiated a phase II trial in South Korea
to evaluate PLacental eXpanded (PLX) cells for the treatment of
intermittent claudication (IC).
The study is being conducted by partner CHA Bio &
We note that CHA Bio & Diostech has an exclusive licensing
agreement with Pluristem to evaluate PLX cells for peripheral
artery disease (PAD) in South Korea.
As per the terms of the agreement, both Pluristem and CHA will
enter into a joint venture to share the revenues and income
generated through sales of PLX cell therapies in the South Korean
market if and when a candidate receives approval in South
We remind investors that Pluristem received approval from the
South Korean Ministry of Food and Drug Safety to conduct trials in
South Korea evaluating the use PLX cells in May 2014.
Meanwhile, trials on PLX cells for the treatment of IC are
ongoing in the U.S., Germany and Israel.
Pluristem develops placenta-based cell therapies in
collaboration with companies like
) or through research and clinical institutions. The cells from
placenta, known as PLX cells, are derived using the company's
proprietary PluriX therapy.
Celgene Cellular Therapeutics, a wholly owned subsidiary of
), is also doing research on stem cells derived from the human
placenta as well as from the umbilical cord for the treatment of
Pluristem currently carries a Zacks Rank #3 (Hold). Investors
looking for better-ranked stocks in the broader healthcare sector
), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
To read this article on Zacks.com click here.